Drug Profile
Gemcitabine liposomal suspension - FUJIFILM Corporation
Alternative Names: F832; FF-10832Latest Information Update: 10 Jul 2022
Price :
$50
*
At a glance
- Originator FUJIFILM Corporation
- Developer FUJIFILM Corporation; Merck & Co
- Class Amines; Antineoplastics; Deoxyribonucleosides; Fluorinated hydrocarbons; Ketones; Pyrimidine nucleosides; Pyrimidines; Small molecules
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 03 Jun 2022 Safety and pharmacokinetics data from a phase I trial in Solid tumours presented at the 58th annual meeting of the American Society of Clinical Oncology (ASCO-2022)
- 01 Jun 2022 Phase-II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05318573)
- 01 Jun 2022 Phase-II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV) (NCT05318573)